Last Updated : November 21, 2019
This annual session is an opportunity for all interested stakeholders to get the latest information about priority initiatives and process changes from CADTH’s pharmaceutical reviews portfolio. Updates on other relevant CADTH initiatives will also be provided. The session also includes an open forum, where attendees can direct questions to CADTH President and CEO Dr. Brian O’Rourke, and other senior staff at CADTH.
Event Date: Monday, November 25, 2019
Time: 1:30 p.m. to 4:00 p.m. EST
Location: Vantage Venues, Garden Hall, 16th Floor, 150 King Street West, Toronto, Ontario
The session will be presented in English and can be attended in person or via live broadcast. There is no charge to attend, but advance registration is required. Registration closes on Tuesday, November 19, 2019.
Full details and the registration link are available on the CADTH website.
Questions may be sent by email to Events@cadth.ca.
CADTH and Canadian Blood Services (CBS) are pleased to announce the establishment of a new interim process for the review of plasma protein products. The interim process builds upon the strengths of both agencies to provide stakeholders with an objective, transparent, evidence-informed review process for plasma protein products. The interim process will be in place while provincial and territorial governments (except Québec) complete a review of PPPs and drug formulary processes in collaboration with CBS, CADTH, as well as other key stakeholders.
The objectives of the interim process for the review of plasma protein products are as follows:
CADTH and CBS have prepared a process in brief document that provides an overview of the new interim process.
The CADTH Therapeutic Review Framework and Process has been updated to include oncology products. A therapeutic review is an evidence-based review of publicly available sources regarding a therapeutic category of drugs or a class of drugs in order to support drug reimbursement decisions and drug policy decisions, and to encourage the optimization of drug therapy. CADTH Therapeutic Reviews may be useful in any scenario where there is uncertainty regarding the comparative clinical effectiveness and cost-effectiveness of drugs in a particular therapeutic category or drug class. These changes have been incorporated into the pan-Canadian Oncology Drug Review (pCODR) Procedures and effective immediately.
To make the application and review process more efficient in specific cases, CADTH offers opportunities for tailored reviews for selected new combination products and subsequent entry non-biologic complex drugs. Going forward, CADTH is expanding the tailored review process to include selected additional drug products, such as new formulations of existing drugs that are eligible for review by CADTH (e.g., those with a new route of administration).
The decision to conduct a tailored review will be made by CADTH on a case-by-case basis after reviewing the applicable considerations form filed by the sponsors. Sponsors planning to file a submission for a new combination product or a new formulation of an existing drug are required to complete and submit a tailored review application form to CADTH (email@example.com) before filing the submission. CADTH will review the provided information and, with input from the drug plans, determine if the drug should undergo a tailored or standard review. CADTH has also updated the tailored review submission template to simplify the document and improve the instructions for sponsors.
Effective immediately, all checkpoint meetings for drugs being reviewed through the CADTH pCODR process will be held via teleconference. CADTH will no longer be offering in-person checkpoint meetings. All sponsors with scheduled checkpoint meetings will be contacted by CADTH to make alternative arrangements. These changes have been incorporated into the pCODR Procedures.
CADTH has undertaken an internal review and established a novel process for the review of cell and gene therapies. This new process will offer stakeholders the benefits of firm performance targets and well-established methods for conducting reviews and issuing recommendations for drug products, with the additional ethical and implementation considerations that are an important strength of CADTH’s medical devices programs. Complete details of the new process for the submission and review of cell and gene therapies will be announced in the near future.
CADTH has been undertaking work to improve and align the procedures for our single drug review processes and the announcement of a new consolidated review process is forthcoming. Highlights of this announcement will include:
Stakeholder feedback on CADTH’s drug program consultations closed on September 27, 2019. CADTH received a total of 28 responses from pharmaceutical companies, government agencies, industry associations and consortia, and consulting firms. CADTH is currently reviewing this feedback and will communicate a summary and next steps at a later date.
CADTH launched the Pharmaceutical Reviews Update in August 2018 to consolidate the communications for its drug review processes. As part of these changes, CADTH will be removing all previous postings for CDR Updates, pCODR Updates, Therapeutic Review Updates, Updates for Patient Groups, as well as older consultation documents. These documents will be consolidated into a single archive document available on the CADTH website. CADTH will continue to routinely remove outdated Web postings and notify stakeholders that the documents have been added to the archive file.